Aleniglipron Explained

Legal Status:	Investigational
Cas Number:	2685823-26-9
Pubchem:	164809721
Drugbank:	DB18551
Iupac Name:	3-[(1''S'',2''S'')-1-[2-[[(4''S'')-3-[3-[4-(Diethylphosphinyl)-3-(methylamino)phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2-(4-fluoro-3,5-dimethylphenyl)-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl]-2-methylcyclopropyl]-1,2,4-oxadiazol-5(2H)-one
C:	49
H:	55
F:	1
N:	9
O:	6
P:	1
Stdinchi:	1S/C49H55FN9O6P/c1-8-66(63,9-2)41-13-11-35(26-38(41)51-7)56-18-19-57(48(56)62)44-42-31(6)55(17-14-37(42)53-59(44)36-22-28(3)43(50)29(4)23-36)45(60)40-25-34-24-33(32-15-20-64-21-16-32)10-12-39(34)58(40)49(27-30(49)5)46-52-47(61)65-54-46/h10-13,18-19,22-26,30-32,51H,8-9,14-17,20-21,27H2,1-7H3,(H,52,54,61)/t30-,31-,49-/m0/s1
Stdinchikey:	CPOJUYUGONJVPZ-WIXASUBBSA-N

Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics.^[1] It is delivered orally and is in a Phase II trial as of 2023.^[2] ^[3] ^[4] In June 2024, Structure Therapeutics reported positive topline data from a Phase 2a obesity study in which GSBR-1290 demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss and generally favorable safety and tolerability results.^[5]

Notes and References

Mao . Ting . Meng . Qinghua . Zhang . Haizhen . Zhang . Jinqiang J. . Shi . Songting . Guan . Zhibo . Jiang . Xinglong . Zhang . Fang . Lei . Hui . Lin . Xichen . 760-P: Discovery of GSBR-1290, a Highly Potent, Orally Available, Novel Small Molecule GLP-1 Receptor Agonist . Diabetes . 20 June 2023 . 72 . Supplement_1 . 10.2337/db23-760-P. 259430363 .
Web site: Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity . BioSpace . 25 May 2023 . 4 November 2023.
Web site: Structure announces positive results from oral GLP-1 receptor agonist gsbr-1290 . Bariatric News . 4 November 2023 . en . 2 October 2023.
News: Satija . Bhanvi . Structure Therapeutics surges as early data from obesity pill tops expectations . 4 November 2023 . Reuters . 29 September 2023 . en.
Web site: 2024-06-03 . Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 . 2024-10-24 . BioSpace . en-US.